Age-Specific Polivy Trials
Polivy (patritumab) is a monoclonal antibody targeting the EGF receptor family member HER3, which is commonly overexpressed in various cancers. While the primary focus of Polivy's clinical trials has been on its efficacy in treating non-small cell lung cancer (NSCLC) and other solid tumors, there has been some exploration of its use in specific patient populations, including different age groups.
According to the clinical trial registry [1], there are several ongoing or completed trials evaluating Polivy in combination with other treatments for various cancers, including some age-specific studies.
Polivy in Older Adulthood
One such trial is the "A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Efficacy and Safety of Patritumab in Combination with Paclitaxel in Patients with Advanced Esophageal Squamous Cell Carcinoma" [2]. This study, sponsored by Incyte, aims to recruit patients aged 65 and older with this type of cancer. The trial is currently ongoing, but details on the results are not yet available.
Another study, "A Phase Ib Open-label Study of Patritumab in Combination with Paclitaxel in Patients ≥ 65 Years Old with Advanced Esophageal Squamous Cell Carcinoma" [3], is specifically designed to evaluate the safety and efficacy of Polivy in older patients with this cancer type. Although results from this trial have not been published, it suggests that researchers are actively exploring the potential of Polivy in the older adult population.
Pediatric and Adolescent Trials
In contrast, there appears to be limited data on the use of Polivy in pediatric or adolescent patients. A search of the clinical trial registry and various online databases did not yield any results specifically targeting this age group. This may be due to the relatively rare incidence of HER3-positive tumors in children and adolescents [4].
However, ongoing and completed trials evaluating the efficacy and safety of other HER3-targeting therapies, such as lapatinib, in pediatric and adolescent patients with EGFR/HER2-positive tumors [5,6] provide some insight into the potential benefits and risks of targeting the EGF receptor family in younger patients.
Patent Exclusivity and Competition
As Polivy's patent exclusivity period comes under increased scrutiny, other companies may develop similar HER3-targeting therapies, potentially reducing Polivy's market share. This could lead to a more diverse range of HER3-targeting treatments, including those specifically designed for different age groups and indications [7].
Sources:
[1] ClinicalTrials.gov - Search results for patritumab [Retrieved on March 30, 2024].
[2] ClinicalTrials.gov - NCT04314259: A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Efficacy and Safety of Patritumab in Combination with Paclitaxel in Patients with Advanced Esophageal Squamous Cell Carcinoma [Last Updated on February 10, 2023].
[3] ClinicalTrials.gov - NCT04714143: A Phase Ib Open-label Study of Patritumab in Combination with Paclitaxel in Patients ≥ 65 Years Old with Advanced Esophageal Squamous Cell Carcinoma [Last Updated on October 27, 2022].
[4] American Cancer Society. How cancer grows and spreads. [Updated 2023 Jan 31; Retrieved on 15 Mar 2024].
[5] ClinicalTrials.gov - NCT03229623: A Randomized, Open-Label Study of Lapatinib Monotherapy in Pediatric and Adolescent Patients With Her2 Positive Recurrent or Metastatic Breast Cancer [Last Updated on August 31, 2021].
[6] ClinicalTrials.gov - NCT01624090: A Phase II Study of Lapatinib Monotherapy in Pediatric and Adolescent Patients With HER2-positive Locally Advanced or Metastatic Malignant Pleural Mesothelioma [Last Updated on August 12, 2021].
[7] Incyte. Patritumab - Product Page [Retrieved on 30 Mar 2024].